The short version
- Why people research itSystemic tissue repair, flexibility and recovery via actin regulation.
- What the evidence isNo randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
- What to watchA new lump that grows.
How TB-500 works
Actin-sequestering peptide that promotes cell migration, angiogenesis and tissue repair — more systemic than local.
TB-500 is LKKTETQ, usually sold with an acetyl cap as Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln. Seven residues, cut out of the middle of a 43-residue protein.
Where the fragment sits. Mature human thymosin beta-4 is 43 residues, and counting along it from the recorded parent sequence in this site's own sequence file puts LKKTETQ at positions 17 to 23. That is the central actin-binding motif, and the authoritative description of the parent protein's active sites credits the short sequence containing LKKTETQ — the actin-binding domain at residues 17 to 23 plus one additional amino acid — with promoting angiogenesis, wound healing and cell migration Sosne 2010.
- Injectable
- Nasal
On the goal map: Satellite cells & local repair (Build muscle & strength)
Research on TB-5005 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
No randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
No completed human trial
Correlative data
Thymosin beta-4 — the full protein TB-500 is a fragment of — reached phase 2 human trials for dry eye and for pressure ulcers, and was tolerated. Those trials tested the parent molecule by a different route for different endpoints, so they establish that the biology is safe to touch in humans and very little else.
Widely used alongside BPC-157 for soft-tissue injury; the reported pattern is slower onset and a broader, more systemic feel than BPC.
How the mechanism reads
An actin-binding fragment. Its mechanism is cell migration — it promotes the movement of the cells that do repair work into the site that needs them, which is a genuinely different mechanism from BPC-157's angiogenic one and the reason the two are stacked rather than swapped.
MechanisticThe same pro-migratory, pro-angiogenic signaling carries the same unanswerable long-term question as BPC-157.
Mechanistic
Sources
- Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal 2010 · PMID 20179146
- Zoubek RE, Hannappel E. Influence of the N terminus and the actin-binding motif of thymosin beta4 on its interaction with G-actin. Annals of the New York Academy of Sciences 2007 · PMID 17495251
- Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration 2003 · PMID 12581423
- Sosne G, et al. Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea 2015 · PMID 25826322
- Guarnera G, et al. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Annals of the New York Academy of Sciences 2007 · PMID 17495250
- Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, Liu C, Bai H, Han C, Sun Y, Liu J. Journal of Cellular and Molecular Medicine 2021 · PMID 34346165
TB-500 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Cancer history or an undiagnosed mass: actin-driven cell migration and angiogenesis help tumors spread and feed.
- Proliferative retinopathy: pro-angiogenic signals can worsen abnormal eye vessels.
- Pregnancy: systemic cell-migration signaling has no safety data.
- A clotting disorder or anticoagulant use, given its effects on endothelial cells.
What’s expected
- Often a diffuse sense of better recovery, as the peptide acts systemically rather than locally.
- Tiredness or a head rush shortly after use.
- Little evidence of effect beyond animal and anecdote.
Watch for
- A new lump that grows.
- Vision change or floaters.
- Calf swelling or chest pain.
- Fever or redness where it is applied.
Labs that tell you it’s working
- hs-CRP (C-Reactive Protein, High Sensitivity)
- Complete Blood Count (CBC) w/ Differential
- ESR (Sed Rate, Westergren)
- Comprehensive Metabolic Panel (CMP)
TB-500 is the active fragment of thymosin beta-4, sequestering actin and promoting cell migration and angiogenesis; evidence is animal and anecdotal. PMID 12581423 PMID 10469335
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
TB-500 FAQ4 common questions
- Is TB-500 approved for human use?
- No. TB-500 is a research compound. No completed randomized human trial has given it yet.
- What is TB-500 researched for?
- Systemic tissue repair, flexibility and recovery via actin regulation.
- Which labs show whether it's doing anything?
- hs-CRP; Complete Blood Count; ESR; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for TB-500: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.





